Comprehensive Stock Comparison
Compare Spero Therapeutics, Inc. (SPRO) vs Cidara Therapeutics, Inc. (CDTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SPRO | -53.8% revenue growth vs CDTX's -94.5% |
| Quality / Margins | SPRO | -122.6% net margin vs CDTX's -133.2% |
| Stability / Safety | CDTX | Beta 0.65 vs SPRO's 0.86, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CDTX | +7.9% vs SPRO's +179.8% |
| Efficiency (ROA) | CDTX | -35.6% ROA vs SPRO's -80.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Spero Therapeutics is a clinical-stage biopharmaceutical company developing novel antibiotics to treat multi-drug resistant bacterial infections and rare diseases. It generates revenue primarily through strategic partnerships and licensing agreements — including deals with Meiji Seika Pharma, Everest Medicines, and the Gates Medical Research Institute — while advancing its pipeline toward commercialization. The company's competitive advantage lies in its focus on addressing urgent unmet medical needs in antimicrobial resistance with innovative oral and IV antibiotic candidates that target difficult-to-treat infections.
Cidara Therapeutics is a biotechnology company developing long-acting anti-infective drugs for serious fungal and viral diseases. It generates revenue primarily through strategic partnerships and licensing agreements — including a major deal with Melinta Therapeutics for its lead antifungal candidate rezafungin — while advancing its proprietary Cloudbreak platform for antiviral conjugates. The company's key advantage is its Cloudbreak platform technology, which enables creation of targeted, long-acting conjugates that combine antiviral or antifungal agents with immune system boosters.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CDTX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). SPRO leads in 2 (Financial Metrics, Valuation Metrics).
Financial Metrics (TTM)
SPRO and CDTX operate at a comparable scale, with $36M and $0 in trailing revenue. SPRO is the more profitable business, keeping -122.6% of every revenue dollar as net income compared to CDTX's -133.2%.
| Metric | SPROSpero Therapeutic… | CDTXCidara Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $36M | $0 |
| EBITDAEarnings before interest/tax | -$45M | -$195M |
| Net IncomeAfter-tax profit | -$44M | -$185M |
| Free Cash FlowCash after capex | -$28M | -$133M |
| Gross MarginGross profit ÷ Revenue | -2.0% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -130.9% | -138.1% |
| Net MarginNet income ÷ Revenue | -122.6% | -133.2% |
| FCF MarginFCF ÷ Revenue | -77.4% | -138.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -77.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +59.4% | -30.3% |
Valuation Metrics
| Metric | SPROSpero Therapeutic… | CDTXCidara Therapeuti… |
|---|---|---|
| Market CapShares × price | $122M | $7.0B |
| Enterprise ValueMkt cap + debt − cash | $74M | $6.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.71x | -8.28x |
| Forward P/EPrice ÷ next-FY EPS est. | 3.24x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 2.55x | 5460.07x |
| Price / BookPrice ÷ Book value/share | 2.54x | 8.61x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CDTX delivers a -43.7% return on equity — every $100 of shareholder capital generates $-44 in annual profit, vs $-165 for SPRO. CDTX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SPRO's 0.09x. On the Piotroski fundamental quality scale (0–9), CDTX scores 3/9 vs SPRO's 1/9, reflecting mixed financial health.
| Metric | SPROSpero Therapeutic… | CDTXCidara Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -165.5% | -43.7% |
| ROA (TTM)Return on assets | -80.9% | -35.6% |
| ROICReturn on invested capital | -3.3% | — |
| ROCEReturn on capital employed | -71.0% | -2.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 0.09x | 0.02x |
| Net DebtTotal debt minus cash | -$49M | -$186M |
| Cash & Equiv.Liquid assets | $53M | $190M |
| Total DebtShort + long-term debt | $4M | $4M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in CDTX five years ago would be worth $48,336 today (with dividends reinvested), compared to $1,154 for SPRO. Over the past 12 months, CDTX leads with a +789.1% total return vs SPRO's +179.8%. The 3-year compound annual growth rate (CAGR) favors CDTX at 94.3% vs SPRO's 13.6% — a key indicator of consistent wealth creation.
| Metric | SPROSpero Therapeutic… | CDTXCidara Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -7.7% | +0.2% |
| 1-Year ReturnPast 12 months | +179.8% | +789.1% |
| 3-Year ReturnCumulative with dividends | +46.6% | +633.0% |
| 5-Year ReturnCumulative with dividends | -88.5% | +383.4% |
| 10-Year ReturnCumulative with dividends | -81.1% | +10.5% |
| CAGR (3Y)Annualised 3-year return | +13.6% | +94.3% |
Risk & Volatility
CDTX is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than SPRO's 0.86 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDTX currently trades 100.0% from its 52-week high vs SPRO's 67.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SPROSpero Therapeutic… | CDTXCidara Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.86x | 0.65x |
| 52-Week HighHighest price in past year | $3.22 | $221.42 |
| 52-Week LowLowest price in past year | $0.51 | $15.22 |
| % of 52W HighCurrent price vs 52-week peak | +67.4% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 40.1 | 84.8 |
| Avg Volume (50D)Average daily shares traded | 237K | 796K |
Analyst Outlook
Wall Street rates SPRO as "Buy" and CDTX as "Buy".
| Metric | SPROSpero Therapeutic… | CDTXCidara Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $177.88 |
| # AnalystsCovering analysts | 13 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Spero Therapeutics,… (SPRO) | 100 | 24.19 | -75.8% |
| Cidara Therapeutics… (CDTX) | 100 | 373.36 | +273.4% |
Cidara Therapeutics… (CDTX) returned +383% over 5 years vs Spero Therapeutics,… (SPRO)'s -88%. A $10,000 investment in CDTX 5 years ago would be worth $48,336 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Spero Therapeutics,… (SPRO) | $0.00 | $48M | — |
| Cidara Therapeutics… (CDTX) | $0.00 | $1M | — |
Spero Therapeutics, Inc.'s revenue grew from $0M (2015) to $48M (2024) — a 0.0% CAGR. Cidara Therapeutics, Inc.'s revenue grew from $0M (2015) to $1M (2024) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2024 | Change |
|---|---|---|---|
| Spero Therapeutics,… (SPRO) | -76.1% | -142.9% | -87.8% |
| Cidara Therapeutics… (CDTX) | -196.5% | -133.2% | +32.2% |
Spero Therapeutics, Inc.'s net margin went from -76% (2016) to -143% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Spero Therapeutics,… (SPRO) | -1.54 | -1.27 | +17.5% |
| Cidara Therapeutics… (CDTX) | -46.76 | -26.75 | +42.8% |
Spero Therapeutics, Inc.'s EPS grew from $-1.54 (2015) to $-1.27 (2024). Cidara Therapeutics, Inc.'s EPS grew from $-46.76 (2015) to $-26.75 (2024).
Chart 5Free Cash Flow — 5 Years
Spero Therapeutics, Inc. generated $-23M FCF in 2024. Cidara Therapeutics, Inc. generated $-177M FCF in 2024 (-599% vs 2021).
SPRO vs CDTX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is SPRO or CDTX a better buy right now?
Analysts rate Spero Therapeutics, Inc. (SPRO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SPRO or CDTX?
Over the past 5 years, Cidara Therapeutics, Inc. (CDTX) delivered a total return of +383.4%, compared to -88.5% for Spero Therapeutics, Inc. (SPRO). A $10,000 investment in CDTX five years ago would be worth approximately $48K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CDTX returned +10.5% versus SPRO's -81.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SPRO or CDTX?
By beta (market sensitivity over 5 years), Cidara Therapeutics, Inc. (CDTX) is the lower-risk stock at 0.65β versus Spero Therapeutics, Inc.'s 0.86β — meaning SPRO is approximately 32% more volatile than CDTX relative to the S&P 500. On balance sheet safety, Cidara Therapeutics, Inc. (CDTX) carries a lower debt/equity ratio of 2% versus 9% for Spero Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — SPRO or CDTX?
Spero Therapeutics, Inc. (SPRO) is the more profitable company, earning -142.9% net margin versus -133.2% for Cidara Therapeutics, Inc. — meaning it keeps -142.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SPRO leads at -152.9% versus -138.1% for CDTX. At the gross margin level — before operating expenses — CDTX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SPRO or CDTX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SPRO or CDTX better for a retirement portfolio?
For long-horizon retirement investors, Cidara Therapeutics, Inc. (CDTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.65)). Both have compounded well over 10 years (CDTX: +10.5%, SPRO: -81.1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SPRO and CDTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.